A Double-blind Study to Compare the Efficacy Safety and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara in Patients With Moderate-to-Severe Plaque Psoriasis

  • End date
    May 26, 2022
  • participants needed
  • sponsor
    Bioeq GmbH
Updated on 11 August 2021


This is a randomized, double-blind, multicenter study to evaluate the efficacy, safety, and immunogenicity of FYB202 compared to Stelara in patients with Moderate-to-Severe Plaque Psoriasis.

Condition Plaque Psoriasis
Treatment FYB202 (Proposed ustekinumab biosimilar), Stelara® (Ustekinumab)
Clinical Study IdentifierNCT04595409
SponsorBioeq GmbH
Last Modified on11 August 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note